Abstract
The combined effect of Naringin (NAR) and Imatinib mesylate (IMT) in Philadelphia positive chronic myeloid leukaemia was studied in vitro and in silico in this study. The chronic myeloid leukemia (CML) is a myeloproliferative hematopoietic cancer caused by a chromosomal translocation t (9;22). (q34; q11). IMT, a Tyrosine Kinase inhibitor that targets the BCR-ABL oncoprotein, is a first-line treatment for CML. IMT is related with the development of resistance due to mutation of Abl kinase domain. Natural compounds generated from plants have been linked to enhanced therapeutic efficacy and fewer adverse effects in cancer patients. Flavonoids, for example, are physiologically active substances with anti-cancer capabilities that influence a number of cellular signalling pathways suppressing a variety of malignancies. The primary goal of combining synthetic medications with phytochemicals is to achieve a therapeutic activity with the greatest pharmacological efficacy. Targeting AKT with flavonoid (NAR) compounds in conjunction with IMT treatment could be extremely beneficial in CML through additive processes. The combined effect of IMT and NAR in the treatment of CML was assessed using a silico molecular docking and long-term in vitro cytotoxicity assay on K562 cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
